CTXR
Citius Pharmaceuticals, Inc.
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We incurred a net loss of $37,503,635 for the six months ended March 31, 2026. The Company experienced negative cash flows from operations of $14,308,843 for the six months ended March 31, 2026. At March 31, 2026, the Company had $4,590,174 in cash and a negative working capital of approximately $23.3 million.”View the 10-Q filed May 15, 2026
Company with tickers: CTXR
CIK
1506251
CUSIP
17322U306
Shares Outstanding
27,452,570
Website
https://www.citiuspharma.com
Investor Relations
https://www.citiuspharma.com/investors/
13F Activity (30d)
3 filings
2 filers
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this stock, matched by the stock's CUSIP. Each row is one fund position with its size, value and weight in that fund.
Funds holding CTXR
5 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND | — | 167,738 | $150,964 | 0.00% | Long | 2026-03-31 | |
| Fidelity Extended Market Index Fund | — | 100,355 | $74,263 | 0.00% | Long | 2026-02-28 | |
| Fidelity Series Total Market Index Fund | — | 19,719 | $14,592 | 0.00% | Long | 2026-02-28 | |
| Fidelity Total Market Index Fund | — | 11,655 | $8,625 | 0.00% | Long | 2026-02-28 | |
| Blackstone Alternative Multi-Strategy Fund | — | 962 | $866 | 0.00% | Short | 2026-03-31 |
Showing 1–5 of 5 positions